Lv41
480 积分 2022-11-10 加入
Sustained Safety and Efficacy of Once‐Daily Hydromorphone Extended‐Release (OROS® hydromorphone ER) Compared with Twice‐Daily Oxycodone Controlled‐Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain
54分钟前
已完结
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
59分钟前
已完结
Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain
1小时前
已完结
Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog
1个月前
已关闭
Morphine and treatment of cancer -related pain-risk or benefit?
3个月前
已完结
Häusliche Behandlung von Tumorschmerzpatienten mit patientenkontrollierter Analgesie (PCA)
3个月前
已关闭
Ambulante kontinuierliche subkutane Opioidanalgesie als PCAO (Patient controlled analgesia in outpatients) bei schweren Tumorschmerzen
3个月前
已关闭
Clinical Pharmacology of Opioids for Pain
3个月前
已完结
Prescription of Controlled Substances: Benefits and Risks
3个月前
已关闭
A Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
6个月前
已完结
皖公网安备34019202002308
